BRPI0413393A - fexofenadina, composição farmaceuticamente aceitável, método de tratamento antihistamìnico, composição, processo para preparar fexofenadina e uso de fexofenadina - Google Patents

fexofenadina, composição farmaceuticamente aceitável, método de tratamento antihistamìnico, composição, processo para preparar fexofenadina e uso de fexofenadina

Info

Publication number
BRPI0413393A
BRPI0413393A BRPI0413393-5A BRPI0413393A BRPI0413393A BR PI0413393 A BRPI0413393 A BR PI0413393A BR PI0413393 A BRPI0413393 A BR PI0413393A BR PI0413393 A BRPI0413393 A BR PI0413393A
Authority
BR
Brazil
Prior art keywords
fexofenadine
composition
preparing
pharmaceutically acceptable
treatment method
Prior art date
Application number
BRPI0413393-5A
Other languages
English (en)
Inventor
Dharmaraj Ramachandra Rao
Rajendra Narayanrao Kankan
Manish Gopaldas Gangrade
Dilip Ramdas Birari
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of BRPI0413393A publication Critical patent/BRPI0413393A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FEXOFENADINA, COMPOSIçãO FARMACEUTICAMENTE ACEITáVEL, MéTODO DE TRATAMENTO ANTIHISTAMìNICO, COMPOSIçãO, PROCESSO PARA PREPARAR FEXOFENADINA E USO DE FEXOFENADINA". A presente invenção refere-se a hidrocloreto de fexofenadina cristalino anidro Forma C, monohidrato de acetato de fexofenadina cristalino Forma D, dihidrato de acetato de fexofenadina cristalino Forma E, e monohidrato de base livre de fexofenadina cristalino Forma F, processos para prepará-los, composições farmacêuticas com os mesmos, usos terapêuticos dos mesmos e métodos para tratamento com os mesmos.
BRPI0413393-5A 2003-08-26 2004-08-25 fexofenadina, composição farmaceuticamente aceitável, método de tratamento antihistamìnico, composição, processo para preparar fexofenadina e uso de fexofenadina BRPI0413393A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0319935.3A GB0319935D0 (en) 2003-08-26 2003-08-26 Polymorphs
PCT/GB2004/003624 WO2005019175A1 (en) 2003-08-26 2004-08-25 Fexofenadine polymorphs and processes of preparing the same

Publications (1)

Publication Number Publication Date
BRPI0413393A true BRPI0413393A (pt) 2006-10-17

Family

ID=28460267

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413393-5A BRPI0413393A (pt) 2003-08-26 2004-08-25 fexofenadina, composição farmaceuticamente aceitável, método de tratamento antihistamìnico, composição, processo para preparar fexofenadina e uso de fexofenadina

Country Status (12)

Country Link
US (2) US7470789B2 (pt)
EP (1) EP1667971B1 (pt)
JP (1) JP2007503423A (pt)
KR (1) KR20070026300A (pt)
AU (1) AU2004266186B2 (pt)
BR (1) BRPI0413393A (pt)
CA (1) CA2537257C (pt)
GB (1) GB0319935D0 (pt)
NZ (2) NZ580808A (pt)
RU (1) RU2352561C2 (pt)
WO (1) WO2005019175A1 (pt)
ZA (1) ZA200601736B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040044038A1 (en) 2002-06-10 2004-03-04 Barnaba Krochmal Polymorphic form XVI of fexofenadine hydrochloride
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
ITMI20041143A1 (it) * 2004-06-08 2004-09-08 Dipharma Spa Polimorfi di fexofenadina e procedimento per la loro preparazione
JP2008514641A (ja) * 2004-09-28 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド 結晶形フェキソフェナジン、およびその調製方法
MX2008001645A (es) * 2005-08-05 2008-04-07 Lupin Ltd Composiciones de fexofendina en suspension farmaceutica oral.
WO2007052310A2 (en) * 2005-11-03 2007-05-10 Morepen Laboratories Limited Polymorphs of fexofenadine hydrochloride and process for their preparation
ITMI20070987A1 (it) * 2007-05-16 2008-11-17 Dipharma Francis Srl Procedimento per la preparazione di composti chetonici
WO2009034582A2 (en) * 2007-09-13 2009-03-19 Ind-Swift Laboratories Limited Process for the preparation of amorphous fexofenadine hydrochloride
US20090306135A1 (en) 2008-03-24 2009-12-10 Mukesh Kumar Sharma Stable amorphous fexofenadine hydrochloride
WO2009136412A2 (en) * 2008-04-25 2009-11-12 Matrix Laboratories Limited PROCESS FOR PREPARATION OF 4-[4-(4-(HYDROXYDIPHENYLMETHYL)- 1-PIPERIDINYL]-1-OXOBUTYL]-α,α-DIMETHYLBENZENE ACETIC ACID METHYL ESTER AND USE THEREOF
PL2432454T3 (pl) 2009-05-19 2017-10-31 Neuroderm Ltd Kompozycje do ciągłego podawania inhibitorów dopa-dekarboksylazy
ES2403130B1 (es) * 2010-06-15 2014-09-29 Chemelectiva S.R.L. Forma polimórfica de clorhidrato de fexofenadina, compuestos intermedios y procedimiento para su preparación
PT2640358T (pt) 2010-11-15 2018-02-23 Neuroderm Ltd Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos
CN102351779A (zh) * 2011-09-07 2012-02-15 浙江华纳药业有限公司 非索非那定中间体的制备方法
ITMI20120589A1 (it) * 2012-04-12 2013-10-13 Chemelectiva S R L Intermedi utili per la sintesi di fexofenadina, processo per la loro preparazione e per la preparazione di fexofenadina
ITMI20132039A1 (it) * 2013-12-06 2015-06-07 Dipharma Francis Srl "metodo per la preparazione di intermedi sintetici"
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
DK3116475T3 (da) 2014-03-13 2020-12-07 Neuroderm Ltd Dopa-decarboxylasehæmmersammensætninger
CN104072402B (zh) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 一种新结晶形式的盐酸非索非那定化合物及其制备方法
CN106380441B (zh) * 2016-08-29 2020-08-14 上海雅本化学有限公司 一种非索非那定中间体的合成方法
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｊａｋファミリーのキナーゼの低分子阻害物質
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
MX2023010642A (es) 2021-03-11 2023-11-28 Janssen Pharmaceutica Nv Lorpucitinib para uso en el tratamiento de trastornos mediados por jak.
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
DK0635004T3 (da) 1992-04-10 2002-11-11 Merrell Pharma Inc 4-Diphenylmethylpiperidinderivater og fremgangsmåde til fremstilling deraf
US5654433A (en) 1993-01-26 1997-08-05 Merrell Pharmaceuticals Inc. Process for piperidine derivatives
EP1369409B1 (en) * 1993-06-24 2006-04-05 AMR Technology, Inc. Process for preparing compounds useful as intermediates
EP1178041A1 (en) 1994-05-18 2002-02-06 Aventis Pharmaceuticals Inc. Process for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives
CN1143680C (zh) * 1997-08-14 2004-03-31 阿旺蒂斯制药公司 增强非索非那定及其衍生物之生物利用度的方法
US6613906B1 (en) 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
CH695216A5 (de) * 2001-02-23 2006-01-31 Cilag Ag Verfahren zur Herstellung eines nicht hydratisierten Salzes eines Piperidinderivats und eine so erhältliche neue kristalline Form eines solchen Salzes.
IL158334A0 (en) * 2001-04-09 2004-05-12 Teva Pharma Polymorphs of fexofenadine hydrochloride
IL159266A0 (en) * 2001-06-18 2004-06-01 Reddys Lab Ltd Dr Crystalline forms of fexofenadine and processes for the preparation thereof
WO2003011295A1 (en) 2001-07-31 2003-02-13 Texcontor Etablissement Fexofenadine polymorph
CA2465913A1 (en) 2001-11-08 2003-05-15 Judith Aronhime Polymorphs of fexofenadine base
US20040044038A1 (en) * 2002-06-10 2004-03-04 Barnaba Krochmal Polymorphic form XVI of fexofenadine hydrochloride
GB0319935D0 (en) * 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
CN1330162C (zh) * 2004-12-02 2007-08-01 华为技术有限公司 一种数据分段级联的方法

Also Published As

Publication number Publication date
CA2537257C (en) 2013-07-16
US8247434B2 (en) 2012-08-21
GB0319935D0 (en) 2003-09-24
AU2004266186B2 (en) 2009-10-22
CA2537257A1 (en) 2005-03-03
JP2007503423A (ja) 2007-02-22
ZA200601736B (en) 2007-05-30
WO2005019175A1 (en) 2005-03-03
US7470789B2 (en) 2008-12-30
KR20070026300A (ko) 2007-03-08
NZ545631A (en) 2009-12-24
AU2004266186A1 (en) 2005-03-03
EP1667971A1 (en) 2006-06-14
US20070191428A1 (en) 2007-08-16
EP1667971B1 (en) 2012-06-20
RU2006109480A (ru) 2007-10-10
NZ580808A (en) 2011-02-25
US20090221830A1 (en) 2009-09-03
RU2352561C2 (ru) 2009-04-20

Similar Documents

Publication Publication Date Title
BRPI0413393A (pt) fexofenadina, composição farmaceuticamente aceitável, método de tratamento antihistamìnico, composição, processo para preparar fexofenadina e uso de fexofenadina
IS8132A (is) Pýrósóló-kínasólín afleiður, aðferð við framleiðslu þeirra og notkun sem kínasa hindrar
BRPI0507786A (pt) composto e sais farmaceuticamente aceitáveis do mesmo, formulação farmacêutica, uso de um composto, método de tratar uma doença, e, processo para a preparação de compostos
PT1326613E (pt) Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos
TW200518743A (en) Rapid dissolution formulation of a calcium receptor-active compound
TW200745111A (en) New compounds
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
ATE361287T1 (de) Neue indol-2-on derivate
SE0104341D0 (sv) New use
WO2005054179A3 (en) Hydroxamic acid esters and pharmaceutical use thereof
DE602004024375D1 (de) Carboxamidderivate
EE04911B1 (et) Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks
BR0008979A (pt) Composto quìmico, uso de um composto, método de tratamento, processo de preparação de um composto, composição farmacêutica e método de fabricação da mesma
UY27592A1 (es) Nuevo uso
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
DK1546127T3 (da) Nye pyrimidinamidderivater og anvendelse deraf
BRPI0416287A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
BRPI0411936A (pt) composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade
BR0308133A (pt) Forma polimórfica cristalina de cloridrato de irinotecan
MY133527A (en) Isoquinoline derivatives
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
SE0102440D0 (sv) New compound
SE0401655D0 (sv) New compounds
TW200800984A (en) New compounds

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.